retatrutide nonalcoholic fatty liver disease nash trial Drug Pipeline for MASLD: What Can Be Learned from the Successful Story of Resmetirom Top Nonalcoholic Fatty Liver Disease

There is no direct milligram-to-milligram conversion

Its rich in growth factors that can help stimulate regrowth and improve density

We work closely with healthcare providers to ensure each patient receives personalized care and the best possible options

Uninsured patients represent one of the fastest-growing populations seeking weight loss medication, driven by rising obesity rates and limited employer-sponsored coverage options

It demonstrates higher potency at the GIP receptor (EC50: 0.0643 nM) relative to the GLP-1 (EC50: 0.775 nM) and glucagon (EC50: 5.79 nM) receptors (Li et al., 2024)

Enhanced Total Fat Loss Retatrutide alone produces approximately 24% total body weight loss at its highest studied dose